Concepedia

Author

Karl L. Banta

University of California, BerkeleyORCID

Also Known As

K L Banta, Karl Banta, Karl L Banta, Karl L. Banta, Karl Luke Banta

21

Publications

1.5K

Citations

9

H-Index

13

Concepts

All Affiliations

University of California, BerkeleyGene Therapy LaboratoryGenesys (United States)UCSF Helen Diller Family Comprehensive Cancer CenterUniversity of California, San Francisco
KL

About

Karl L. Banta is an author at University of California, Berkeley specializing in cancer research, medicine, and lung cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

855

2

Cell Biology

1

1

85

3

Immunology

1

1

770

4

Pathology

1

1

770

5

Cancer Genetics

1

1

85

Karl L. Banta

×

9

Publications

1.5K

Citations

9

H-Index

YearCitations

Peripheral T cell expansion predicts tumour infiltration and clinical response

Thomas D. Wu, Shravan Madireddi, Patrícia E. de Almeida,

Nature

2020

770

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses

Karl L. Banta, Xiaozheng Xu, Avantika S. Chitre,

Immunity

2022

324

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

Xiangnan Guan, Ruozhen Hu, Yoonha Choi,

Nature

2024

102

CD96 functions as a co‐stimulatory receptor to enhance CD8 <sup>+</sup> T cell activation and effector responses

Eugene Y. Chiang, Patricia E. de Almeida, Denise E. de Almeida Nagata,

European Journal of Immunology

2020

94

Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis

Minh D. To, Reyno Del Rosario, Peter M.K. Westcott,

Oncogene

2012

85

B cell lymphoma 2 (Bcl-2) residues essential for Bcl-2's apoptosis-inducing interaction with Nur77/Nor-1 orphan steroid receptors

Karl L. Banta, Xinyue Wang, Phani B. Das,

Journal of Biological Chemistry

2018

30

TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation

Katherine Nutsch, Karl L. Banta, Thomas D. Wu,

Nature Cancer

2024

29

Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL)

Franck Morschhauser, Krish Patel, Sabela Bobillo,

Blood

2023

14

Sequential mutations in Notch1, Fbxw7, and Tp53 in radiation-induced mouse thymic lymphomas

Kuang‐Yu Jen, Ihn Young Song, Karl L. Banta,

Blood

2011

13

Page 1